Liver Disease News and Research

RSS

The liver is one of the largest solid organs of the body. It is located in the upper right part of the abdomen. Most of the organ lies under cover of the rib cage.

Daclatasvir-sofosbuvir treatment highly effective in patients with HCV and HIV co-infection

Phase III results revealed today at The International Liver Congress 2015 show that once-daily treatment with daclatasvir (DCV) plus sofosbuvir (SOF) resulted in an overall 97% sustained virologic response (SVR) at 12 weeks post-treatment in patients with hepatitis C virus (HCV) and HIV co-infection, including cirrhotic patients.

23 Apr 2015

Study: Combination therapy shows high SVR rates in HCV patients with decompensated liver disease

Results presented today at The International Liver Congress 2015 show that the use of the fixed-dose combination of ledipasvir/sofosbuvir (LDV/SOF) in combination with ribavirin (RBV) was well tolerated and demonstrated high sustained virologic response rates 12 weeks post treatment (SVR12) in patients with chronic hepatitis C virus (HCV) infection who have decompensated liver disease (cirrhosis) or have undergone liver transplantation.

23 Apr 2015

Diabetes drug liraglutide could prove to be a new treatment option for NASH

A drug approved to treat type 2 diabetes could prove to be a powerful new treatment option for non-alcoholic steatohepatitis (NASH), according to research presented today at The International Liver Congress 2015. Results from a randomised controlled trial showed liraglutide met the primary endpoint of histological clearance of NASH, and a reduction in the progression of fibrosis.

23 Apr 2015

Exome sequencing helps identify link between environmental exposures and mutational patterns in HCC

A new study presented today at The International Liver Congress 2015 shows that by using genomic analyses to understand how and when carcinogenic mutations occur in patients with hepatocellular carcinoma (HCC), it is possible to identify specific molecular profiles. It is hoped that these molecular profiles will help identify which patients would benefit from specific anticancer treatments.

23 Apr 2015

Remogliflozin etabonate: A potential treatment option for management of NASH and NAFLD

Data presented today at The International Liver Congress 2015 demonstrates that remogliflozin etabonate, an investigational drug in type 2 diabetes, is a potential treatment option for the management of patients with non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).

23 Apr 2015

Long-term ETV or TDF therapy improves survival rate for Caucasian patients with CHB

Data revealed today at The International Liver Congress 2015 show that the long-term use of entecavir (ETV) or tenofovir (TDF) results in excellent 5-year survival for Caucasian patients with chronic hepatitis B (CHB), with more than 95% of patients surviving at 5 years and a significant proportion of deaths coming from liver-unrelated causes.

23 Apr 2015

Study calls for better surveillance to prevent spread of viral hepatitis in WHO European Region

Many countries in the World Health Organization European Region are facing limitations in conducting chronic viral hepatitis disease surveillance, assessing the burden of disease and measuring the impact of interventions, according to results revealed today at The International Liver Congress 2015.

23 Apr 2015

Transportable MP Airdrive device enhances donor liver viability for transplantation

A new device has demonstrated it has the potential to enhance the viability of donor livers for transplantation. Results revealed today at The International Liver Congress 2015 show that the transportable machine perfusion (MP) Airdrive is able to effectively maintain the quality of livers derived from donation after circulatory death (DCD).

23 Apr 2015

Survey: Nearly half of people infected with viral hepatitis suffer discrimination

As many as half of people infected with viral hepatitis have suffered discrimination and one-quarter admit that family members have avoided physical contact with them after finding out they had the infection. A shocking patient survey presented at The International Liver Congress 2015 has shown the devastating impact the infection has on their daily lives.

23 Apr 2015

Non-alcoholic fatty liver disease can promote development of coronary artery calcification

Data revealed today at The International Liver Congress 2015 show that non-alcoholic fatty liver disease (NAFLD) plays a role in the early stages of coronary atherosclerosis and in its more severe form it can also promote the development of coronary artery calcification (CAC).

23 Apr 2015

Study supports use of vitamin E as effective treatment for NASH

Results revealed today at The International Liver Congress 2015 show that vitamin E (d-alpha-tocopherol) is an effective treatment for non-alcoholic steatohepatitis (NASH). NASH occurs when the liver becomes inflamed due to the accumulation of fat. Over time, persistent inflammation can lead to the formation of fibrous scar tissue in the liver and around its blood vessels, which can eventually cause cirrhosis.

23 Apr 2015

Novel immunotherapeutic shows promise against chronic hepatitis B

A novel immunotherapeutic in early development for chronic hepatitis B (CHB), TG1050, has been shown to reach the clinical goals that are considered to be the hallmarks of a cure for CHB, according to results revealed today at The International Liver Congress 2015.

23 Apr 2015

Civacir can effectively prevent HCV recurrence following liver transplants

New data from an ongoing Phase III trial revealed today at The International Liver Congress 2015 show that the use of hepatitis C immune globulin (HCIG, Civacir) can effectively prevent hepatitis C virus (HCV) recurrence in patients following a liver transplant (LT).

23 Apr 2015

Study reveals impact of delaying HCV treatment

Data revealed today at The International Liver Congress 2015 highlights the impact of delaying treatment for the hepatitis C virus (HCV). Researchers found that treatment delays have a serious detrimental effect on treatment efficacy, increasing the risk of morbidity and mortality among patients.

23 Apr 2015

Capsaicin has beneficial effects on liver damage, study reveals

Results revealed today at the International Liver Congress 2015 show that the daily consumption of capsaicin, the active compound of chilli peppers, was found to have beneficial effects on liver damage.

23 Apr 2015

Baclofen has positive impact on alcohol consumption in patients with ALD

Results revealed today at The International Liver Congress 2015, show that in patients with alcohol-induced liver disease (ALD), Baclofen has a positive impact on alcohol consumption and overall measures of liver function and harm.

23 Apr 2015

HCV-TARGET study: All-oral, direct-acting antiviral therapy for HCV effective in decompensated cirrhosis patients

Interim data presented today at The International Liver Congress 2015 from the HCV-TARGET study show that all-oral, direct-acting antiviral therapy for hepatitis C (HCV) is well tolerated and highly effective in patients with decompensated cirrhosis.

23 Apr 2015

Study: Alginate-enriched bread can reduce fat digestion, circulatory lipids in NAFLD patients

A study revealed today at The International Liver Congress 2015 has demonstrated that alginate-enriched bread has the potential to inhibit fat digestion and circulatory lipids in patients with non-alcoholic fatty liver disease (NAFLD).

23 Apr 2015

May issues of AGA's journals highlight important research updates on liver disease

The May issues of AGA's journals -- Clinical Gastroenterology and Hepatology and Gastroenterology -- highlight important research updates on the most deadly forms of liver disease.

23 Apr 2015

New educational resource to help improve knowledge, treatment of Inflammatory Bowel Disease

A new educational resource for doctors and healthcare professionals will help improve knowledge and treatment of Inflammatory Bowel Disease (IBD). The Inflammatory Bowel Disease Resource Centre was developed by Elsevier, the journal Digestive and Liver Disease, and was made possible through an educational grant from Ferring Pharmaceuticals.

22 Apr 2015

Liver Disease News and Research

Further Reading

Daclatasvir-sofosbuvir treatment highly effective in patients with HCV and HIV co-infection

Study: Combination therapy shows high SVR rates in HCV patients with decompensated liver disease

Diabetes drug liraglutide could prove to be a new treatment option for NASH

Exome sequencing helps identify link between environmental exposures and mutational patterns in HCC

Remogliflozin etabonate: A potential treatment option for management of NASH and NAFLD

Long-term ETV or TDF therapy improves survival rate for Caucasian patients with CHB

Study calls for better surveillance to prevent spread of viral hepatitis in WHO European Region

Transportable MP Airdrive device enhances donor liver viability for transplantation

Survey: Nearly half of people infected with viral hepatitis suffer discrimination

Non-alcoholic fatty liver disease can promote development of coronary artery calcification

Study supports use of vitamin E as effective treatment for NASH

Novel immunotherapeutic shows promise against chronic hepatitis B

Civacir can effectively prevent HCV recurrence following liver transplants

Study reveals impact of delaying HCV treatment

Capsaicin has beneficial effects on liver damage, study reveals

Baclofen has positive impact on alcohol consumption in patients with ALD

HCV-TARGET study: All-oral, direct-acting antiviral therapy for HCV effective in decompensated cirrhosis patients

Study: Alginate-enriched bread can reduce fat digestion, circulatory lipids in NAFLD patients

May issues of AGA's journals highlight important research updates on liver disease

New educational resource to help improve knowledge, treatment of Inflammatory Bowel Disease

Pioneering Live Cell Imaging - Yokogawa's Impact and Innovations

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Latest News